A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink

BACKGROUND: The long-acting anticholinergic (LAMA) aclidinium was approved in Europe in 2012 to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). A Post-Authorisation Safety Study (PASS) was initiated to assess potential cardiovascular safety concerns for aclidinium. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebordosa, Cristina, Plana, Estel, Rubino, Annalisa, Aguado, Jaume, Lei, Alejhandra, Daoud, Sami, Saigi-Morgui, Nuria, Perez-Gutthann, Susana, Rivero-Ferrer, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180309/
https://www.ncbi.nlm.nih.gov/pubmed/34103906
http://dx.doi.org/10.2147/COPD.S301624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180309/
https://www.ncbi.nlm.nih.gov/pubmed/34103906
http://dx.doi.org/10.2147/COPD.S301624

Ejemplares similares